Peripheral neuropathies during biologic therapies

References

• Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007; 370(9602):1861–74.
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Silman AJ, Watson KD, Symmons DP. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis. 2004;63(12):1538–43.
   PubMed Web of Science ®Google Scholar
• Nozaki K, Silver RM, Stickler DE, Abou-Fayssal NG, Giglio P, Kamen DL, et al. Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. Am J Med Sci. 2011;342(5):352–5.
   PubMed Web of Science ®Google Scholar
• Tristano AG. Neurological adverse events associated with anti-tumor necrosis factor α treatment. J Neurol. 2010;257(9):1421–31.
   PubMed Web of Science ®Google Scholar
• Bosch X, Saiz A, Ramos-Casals M;BIOGEAS Study Group. Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol. 2011;7(3):165–72.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Escalera C, Belzunegui J, Lopez-Dominguez L, Gonzalez C, Figueroa M. Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy. Rheumatology (Oxford). 2005;44(1):132–3.
   PubMed Web of Science ®Google Scholar
• Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum. 2006; 54(5):1429–34.
   PubMed Web of Science ®Google Scholar
• Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – First Revision. J Peripher Nerv Syst. 2010;15(3):1–9.
   Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.
   PubMed Web of Science ®Google Scholar
• Miller FW, Hess EV, Clauw DJ, Hertzman PA, Pincus T, Silver RM, et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum. 2000;43(2):243–9.
   PubMed Web of Science ®Google Scholar
• Parida S. Clinical causality assessment for adverse drug reactions. Indian J Anaesth. 2013;57(3):325–6.
   PubMedGoogle Scholar
• Silburn S, McIvor E, McEntegart A, Wilson H. Guillain–Barré syndrome in a patient receiving anti-tumor necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature. Ann Rheum Dis. 2008; 67(4):575–6.
   PubMed Web of Science ®Google Scholar
• Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44(12):2862–9.
   PubMed Web of Science ®Google Scholar
• Seror R, Richez C, Sordet C, Rist S, Gossec L, Direz G, et al.; Club Rhumatismes et Inflammation Section of the SFR. Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. Rheumatology (Oxford). 2013;52(5):868–74.
   PubMed Web of Science ®Google Scholar
• Cisternas M, Gutiérrez M, Jacobelli S. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al. Arthritis Rheum. 2002;46(11):3107–8. author reply:3108–9.
   PubMed Web of Science ®Google Scholar
• Bouchra A, Benbouazza K, Hajjaj-Hassouni N. Guillain–Barré in a patient with ankylosing spondylitis secondary to ulcerative colitis on infliximab therapy. Clin Rheumatol. 2009;28(Suppl.1):S53–5.
   PubMed Web of Science ®Google Scholar
• Kurmann PT, van Linthoudt D, So AK. Miller–Fisher syndrome in a patient with rheumatoid arthritis treated with adalimumab. Clin Rheumatol. 2009;28(1):93–4.
   PubMed Web of Science ®Google Scholar
• Solomon AJ, Spain RI, Kruer MC, Bourdette D. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler. 2011;17(12):1472–87.
   PubMed Web of Science ®Google Scholar
• Alshekhlee A, Basiri K, Miles JD, Ahmad SA, Katirji B. Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists. Muscle Nerve. 2010;41(5):723–7.
   PubMed Web of Science ®Google Scholar
• Hamon MA, Nicolas G, Deviere F, Letournel F, Dubas F. Demyelinating neuropathy during anti-TNF alpha treatment with a review of the literature. Rev Neurol. 2007;163(12):1232–35.
   PubMed Web of Science ®Google Scholar
• Richez C, Blanco P, Lagueny A, Schaeverbeke T, Dehais J. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology. 2005;64(8):1468–70.
   PubMed Web of Science ®Google Scholar
• Hooper DR, Tarnopolsky MA, Baker SK. Lewis–Sumner syndrome associated with infliximab therapy in rheumatoid arthritis. Muscle Nerve. 2008;38(4):1318–25.
   PubMed Web of Science ®Google Scholar
• Jarand J, Zochodne DW, Martin LO, Voll C. Neurological complications of infliximab. J Rheumatol. 2006;33(5):1018–20.
   PubMed Web of Science ®Google Scholar
• Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol. 2009;66(4):490–7.
   PubMedGoogle Scholar
• Eguren C, Díaz Ley B, Daudén E, García-Diez A, Losada M. Peripheral neuropathy in two patients with psoriasis in treatment with infliximab. Muscle Nerve. 2009;40(3):488–9.
   PubMed Web of Science ®Google Scholar
• Hanaoka BY, Libecco J, Rensel M, Hajj-Ali RA. Peripheral mononeuropathy with etanercept use: case report. J Rheumatol. 2008;35(1):182.
   PubMed Web of Science ®Google Scholar
• Tektonidou MG, Serelis J, Skopouli FN. Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment. Clin Rheumatol. 2007;26(2):258–60.
   PubMed Web of Science ®Google Scholar
• Cocito D, Bergamasco B, Tavella A, Poglio F, Paolasso I, Costa P, et al. Multifocal motor neuropathy during treatment with infliximab. J Peripher Nerv Syst. 2005;10(4):386–7.
   PubMed Web of Science ®Google Scholar
• Paolazzi G, Peccatori S, Cavatorta FP, Morini A. A case of spontaneously recovering multifocal motor neuropathy with conduction blocks (MMNCB) during anti-TNF alpha therapy for ankylosing spondylitis. Clin Rheumatol. 2009;28(8):993–5.
   PubMed Web of Science ®Google Scholar
• Singer OC, Otto B, Steinmetz H, Ziemann U. Acute neuropathy with multiple conduction blocks after TNFalpha monoclonal antibody therapy. Neurology. 2004;63(9):1754.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Makridou A, Karanasios P, Makris N. Axonal common peroneal nerve palsy and delayed proximal motor radial conduction block following infliximab treatment. J Pain Symptom Manage. 2009;38(5):e3–e5.
   PubMedGoogle Scholar
• Kiltz U, Fendler C, Braun J. Neuromuscular involvement in rheumatic patients treated with anti-tumor necrosis factor therapy–three examples. J Rheumatol. 2008;35(10):2074–76.
   PubMed Web of Science ®Google Scholar
• Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, Emery P. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol. 2003;30:2287–91.
   PubMed Web of Science ®Google Scholar
• Makol A, Grover M. Adalimumab induced mononeuritis multiplex in a patient with refractory rheumatoid arthritis: a case report. Cases J. 2008;1(1):287.
   PubMedGoogle Scholar
• Richette P, Dieudé P, Damiano J, Lioté F, Orcel P, Bardin T. Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. J Rheumatol. 2004;31(10):2079–81.
   PubMed Web of Science ®Google Scholar
• Alexopoulou A, Koskinas J, Soultati A, Katsaounis P, Kilidireas K, Papageorgiou C, et al. Acute bilateral phrenic neuropathy following treatment with adalimumab. Clin Rheumatol. 2009;28(11):1337–40.
   PubMed Web of Science ®Google Scholar
• Berthelot CN, George SJ, Hsu S. Distal lower extremity paresthesia and foot drop developing during adalimumab therapy. J Am Acad Dermatol. 2005;53(Suppl 1):S260–2.
   Web of Science ®Google Scholar
• Morimatu A, Iikuni H, Shirota A, Yamane K. (Case report:title and abstract in Japanese). Rinsho Shinkei. 2010;50(8):597.
   Google Scholar
• Abe S, Yoshihara K, Yokoyama K, Matsuda S, Terashima K, Kouyama K, et al. Neurological complication related to Infliximab therapy for rheumatoid arthritis. Mod Rheumatol. 2009;19(Suppl):S204–5.
   PubMed Web of Science ®Google Scholar
• Fukushima T, Waraya M, Mitamura T, Uchibori A, Chiba A. (Case report:title and abstract in Japanese). In the proceeding of the 1139th Annual Meeting of Chiba medical Association. Chiba Med J. 2008;84(1):47.
   Google Scholar
• Nishimura T, Narise, H, Nagashima Y, Maekawa R, Etoh T, Hida A, et al. (Case report:title and abstract in Japanese). In the proceeding of the 586th Annual Meeting of the Kanto Chapter of Japanese Society of Internal medicine. 2012. p. 32.
   Google Scholar
• Ishigaki K, Seto Y, Shiojiri Y, Takayama Y, Karasawa C, Tanaka S, et al. A case with inflammatory myositis and axonal peripheral neuropathy following anti-TNF therapy. Mod Rheumatol. 2008;18(Suppl):158–159.
   Google Scholar
• Ohashi N, Ueno A, Kuronuma Y, Saitoh Y, Takeda T, Nakati R, et al. (Case report:title and abstract in Japanese). Rinsho Shinkei. 2011;51(9):717.
   Google Scholar
• Sugiura F, Kojima T, Oguchi T, Urata S, Yuzawa Y, Sakakibara A, et al. A case of peripheral neuropathy and skin ulcer in a patient with rheumatoid arthritis after a single infusion of tocilizumab. Mod Rheumatol. 2009;19(2):199–03.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;36(5):898–906.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):189–94.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis. 2011;70(12):2148–51.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol. 2012;22(4):498–508.
   PubMed Web of Science ®Google Scholar
• Stübgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve. 2008;37(3):281–92.
   PubMed Web of Science ®Google Scholar